News Release
Bristol Myers Squibb Joins Big Pharma’s Race to Dominate Oncology
MarketJar
Leading pharmaceutical companies are diving headfirst into oncology, sparking a buzz in the cancer treatment world. Bristol Myers Squibb is the latest company to join the movement, announcing its plan to acquire Mirati Therapeutics in a deal valued at up to $5.8 billion 1. This strategic move aims to enhance BMS's oncology portfolio with Mirati's compound, MRTX1719, which holds promise for certain lung cancers, was a key draw. The acquisition received unanimous approval from both companies' boards of directors. Bristol Myers Squibb's CFO and CEO-elect, Chris Boerner, highlighted the importance of this move, emphasizing that the acquisition of Mirati is another substantial step in their endeavor to expand their diversified oncology portfolio and reinforce Bristol Myers Squibb's pipeline for the latter half of the decade and beyond. Eli Lilly, a prominent American pharmaceutical giant, is another major player that has joined this trend with its acquisition of cancer therapy company Point Biopharma Global, for $1.4 billion 2. Point specializes in radioligand therapies, particularly for advanced-stage prostate cancer patients unresponsive to hormonal treatments. Pfizer and Amgen also made the headlines earlier this year with strategic acquisitions of small oncology companies. These multi-billion-dollar transactions, combined with rising cancer awareness efforts and an uptick in global cancer incidences, have rocketed the cancer therapy market to a whopping $158 billion in 2020. This trajectory is only expected to rise, targeting a 9.15% CAGR and aiming for a $268 billion value by 2026. 3 Among the oncology companies developing therapies for this growing market is Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF), a Canadian biopharmaceutical company specializing in immune-oncology therapies and drug delivery technologies, could find themselves in the same spot as Mirati Therapeutics or Point Biopharma Global. Defence Therapeutics is dedicated to advancing the next generation of vaccines, anticancer therapeutics and ADC products using its proprietary platform. Central to Defence Therapeutics ' platform is the Accum® technology, which enables the precise delivery of biomedicines in their intact form to target cells. This innovation promises increased efficacy and potency against severe illnesses like cancer and infectious diseases. Breakthrough AccuTOX ™ -Chitosan Formulation Shows Lymphoma Treatment Potential Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) just reported a significant breakthrough. Their novel AccuTOX ™ -chitosan encapsulated formulation has proven effective in inhibiting the growth of established solid lymphomas, resulting in gradual tumor shrinkage over time. The study had two primary goals: firstly, to determine if AccuTOX ™ could be successfully administered systemically when encapsulated in chitosan-based nanoparticles, and secondly, to assess whether this approach could work in synergy with commonly used immune-checkpoint blockers in oncology. The formulation was administered twice with a two-week interval, and the treated animals were monitored for up to 40 days. Impressively, the tumors in animals receiving AccuTOX ™ -Chitosan injections, along with co-administered anti-PD-1, regressed, and the animals exhibited prolonged survival rates. “The AccuTOX ™ molecule can be toxic if delivered unconjugated and/or systemically. The Defence team was able to bypass this limitation by encapsulating it into chitosan-based nanoparticles,” explained Sebastien Plouffe, CEO of Defence Therapeutics. “This is a simpler and cheaper method compared to the use of antibodies, and may represent a key component of Defence’s future encapsulation strategies''. Chitosan, a linear polysaccharide composed of deacetylated and acetylated units, has a wide range of commercial and biomedical applications. Aside from its uses in agriculture and industry, it is employed in bandages to reduce bleeding and as an antibacterial agent. Chitosan can also facilitate drug delivery through the skin. Leveraging it as a delivery vehicle for unconjugated Accum® or its variants has the potential to revolutionize molecular medicine. This approach could increase compound specificity at tumor sites while minimizing the required dosage and, consequently, reducing associated side effects. By innovatively encapsulating the AccuTOX ™ molecule, Defence Therapeutics has not only achieved remarkable tumor regression but also highlighted a potential direction for future molecular medicine endeavors. As researchers and companies continue to push boundaries in the quest for cancer solutions, this advancement underscores the immense potential of integrating existing materials like chitosan with novel therapeutic agents. It's a beacon of hope in the ongoing fight against lymphoma and a testament to the unyielding spirit of medical innovation. For more information about Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) and its Accum® technology, click here or visit their website. Footnotes: [1] https://www.foxbusiness.com/markets/bristol-myers-squibb-buy-cancer-drugmaker-mirati-therapeutics-billion-deal [2] https://www.forbes.com/sites/anafaguy/2023/10/03/eli-lilly-acquiring-cancer-therapy-developer-for-14-billion-a-nearly-90-premium/ [3] https://www.mordorintelligence.com/industry-reports/cancer-therapy-market Disclosure: 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Defence Therapeutics Inc. Market Jar Media Inc. has or expects to receive from Defence Therapeutics Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) ninety six thousand five hundred US dollars for 30 days (21 business days). 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Defence Therapeutics Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Defence Therapeutics Inc.’s industry; (b) market opportunity; (c) Defence Therapeutics Inc.’s business plans and strategies; (d) services that Defence Therapeutics Inc. intends to offer; (e) Defence Therapeutics Inc.’s milestone projections and targets; (f) Defence Therapeutics Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Defence Therapeutics Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Defence Therapeutics Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Defence Therapeutics Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Defence Therapeutics Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) the accuracy of budgeted costs and expenditures; (e) Defence Therapeutics Inc.’s ability to attract and retain skilled personnel; (f) political and regulatory stability; (g) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (h) changes in applicable legislation; (i) stability in financial and capital markets; and (j) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Defence Therapeutics Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Defence Therapeutics Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Defence Therapeutics Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Defence Therapeutics Inc.’s business operations (e) Defence Therapeutics Inc. may be unable to implement its growth strategy; and (f) increased competition.Except as required by law, Defence Therapeutics Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Defence Therapeutics Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Defence Therapeutics Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Defence Therapeutics Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Defence Therapeutics Inc. or such entities and are not necessarily indicative of future performance of Defence Therapeutics Inc. or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com
October 17, 2023 09:00 AM Eastern Daylight Time
Image
News Release
